Tavexia Lifecare Limited has announced its strategic entry into the pharmaceutical sector, establishing it as a new growth vertical. This expansion aligns with the company’s diversification strategy and aims to leverage the robust growth of India’s pharmaceutical market, projected to reach US$130 billion by 2030. The move is expected to broaden Tavexia’s addressable market and create new avenues for long-term business growth.
Tavexia Lifecare Enters Pharmaceutical Market
Tavexia Lifecare Limited has officially expanded its business operations by entering the pharmaceutical sector, marking it as a significant new growth vertical. This strategic move is integral to the company’s broader strategy of enhancing its presence within the healthcare ecosystem through diversification and sustained growth.
Diversification Strategy and Market Opportunity
The expansion into pharmaceuticals is designed to complement Tavexia’s existing lifecare business. The company plans to explore opportunities across the entire pharmaceutical value chain, including products, active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, and related manufacturing activities. This diversification is particularly timely given the strong growth trajectory of the Indian pharmaceutical market. Currently valued at approximately US$60 billion, it is forecasted to reach around US$130 billion by 2030. India’s pharmaceutical exports have also seen substantial growth, reaching nearly US$30.47 billion in FY2024-25, highlighting the nation’s growing importance in global healthcare supply chains.
Leveraging Growth and Future Outlook
For Tavexia, this new vertical presents a valuable opportunity to diversify its revenue base and capitalize on the broader expansion of India’s healthcare sector. The company anticipates that this strategic addition will foster greater opportunities for partnerships, advanced product development, and robust long-term business growth. Mr. Mit Tarunkumar Brahmbhatt, Chairman and Managing Director, stated, “Our core lifecare business remains central to Tavexia’s growth journey, and the addition of pharmaceuticals is a natural extension of our presence in the broader healthcare ecosystem.” He further emphasized the focus on disciplined execution and developing sustainable business capabilities to create long-term value.
Source: BSE
